2Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022
Category: Press release
Positive Readouts for Transgene’s Clinical Stage Candidates Generated by its Two Innovative Platforms, with Further Clinical Data Expected in the Second Half of 2022
2022 Half-year results and business update
Transgene announces Upcoming Investor Meetings
Transgene announces upcoming investor meetings
Transgene and BioInvent announce clinical trial collaboration and supply agreement with MSD to evaluate BT-001 in combination with KEYTRUDA®
Transgene and bioinvent announce clinical collaboration
Transgene and BioInvent announce positive progress for BT-001
Transgene presented additional Phase I Data with TG4050 at ASCO 2022
Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022
Transgene presented additional Phase I Data with TG4050 at ASCO 2022
Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022
Transgene to present updated positive preliminary data at ASCO 2022
Transgene’s Combined General Meeting of May 25, 2022
Transgene’s combined general meeting of May 25, 2022
Transgene Announces Upcoming Investor Meetings
Transgene annonces upcoming investor meetings
All of Transgene’s preclinical and clinical assets progressed in line with expectations in Q1 2022
All of Transgene’s preclinical and clinical assets progressed in line with expectations in Q1 2022
